Status:

COMPLETED

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Breast Neoplasms

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early bre...

Eligibility Criteria

Inclusion

  • Histologically confirmed HER2-positive primary breast cancer
  • No evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neo-adjuvant or adjuvant)
  • Completed neo-adjuvant chemotherapy prior to entry, if received
  • At least 8 remaining cycles out of the total 18 planned 3-week cycles, if received IV Herceptin
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion

  • History of other malignancy, except for ductal carcinoma in situ of the breast, curatively treated carcinoma in situ of the cervix, basal cell carcinoma, or other curatively treated malignancies of which the participant has been disease-free for at least 5 years
  • Inadequate bone marrow function
  • Impaired liver function
  • Inadequate renal function
  • Serious cardiovascular disease
  • Human immunodeficiency virus or hepatitis B or C infection
  • Prior maximum cumulative dose of doxorubicin greater than (\>) 360 milligrams per meter-squared (mg/m\^2) or epirubicin \>720 mg/m\^2 or equivalent

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2015

Estimated Enrollment :

488 Patients enrolled

Trial Details

Trial ID

NCT01401166

Start Date

October 1 2011

End Date

December 1 2015

Last Update

March 6 2017

Active Locations (75)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 19 (75 locations)

1

Barrie, Ontario, Canada, L4M 6M2

2

Brampton, Ontario, Canada, L6R 3J7

3

Kitchener, Ontario, Canada, N2G 1G3

4

Sault Ste. Marie, Ontario, Canada, P6A 2C4